Curriculum Vitae - University of Washingtondepts.washington.edu/psychadd/RIES_CV_1-2013R.pdfduring ECT. Biological Psychiatry 20:94-119, 1985. 23. Ries RK: DSM-III implications of

1

Curriculum Vitae

Richard K. Ries, M.D.

Personal Data: Place of birth: Seattle, Washington Family Status: Married (Sarah Ries), one child Business address and phone number:

Harborview Medical Center, Box 359911 326 Ninth Avenue Seattle WA 98104 (206)897-4216 (206)679-3837 (cell) (206)744-3236 (FAX) [email protected]

Education: Stanford University, 1966-1970

Northwestern Medical School, 1971-1975

Postgraduate Training:

Psychiatry Residency, University of Washington, Seattle, 1975-1978.

Faculty Positions

Held: Chief Resident, Psychiatry, University of Washington Medical

School, 1978-1979. Acting Instructor, University of Washington Medical School,

1978-1979. Instructor, University of Washington Medical School, 1979-1981. Assistant Professor, University of Washington Medical School,

1981-1985. Associate Professor, University of Washington Medical School,

1985-1998. Professor, University of Washington Medical School, 1998-

present.

Hospital Positions Held:

Attending Psychiatrist, Emergency Medicine Service, University of Washington Medical Center, 1978-1981.

Assistant Director, Psychiatric Consultation-Liaison Service, University of Washington Medical Center, 1979-1981.

Attending Psychiatrist, Inpatient Psychiatry, University of Washington Medical Center, 1981-1988.

Director, Inpatient Psychiatry Services, Harborview Medical Center, 1988-1992.

Director, Harborview Chemical Dependency Project, 1988-present. Director, Harborview Dual Disorders Programs, 1988-present. Director, Outpatient Mental Health Services, Harborview Medical

Center, 1992-2007.

Richard K. Ries, 2/11/13

2

Director, Addictions Division, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, 1999-present.

Honors: Outstanding Resident of Psychiatry, University of Washington

1977-1978. Chief Resident in Psychiatry, University of Washington, 1978-

1979. Candidate for Distinguished Teacher Award, University of

Washington Medical School, 1984-1985. Top Ten Abstracts of 1984, “Tricyclic Antidepressant Therapy for

Peptic Ulcer Disease,” Archives of Internal Medicine (Modern Medicine), March 1984.

Nancy Roeske Award (for medical student teaching), America Psychiatric Association 1992.

Achievement Award, Center for Substance Abuse Treatment, Washington DC, 1995.

Award of Appreciation, Washington Advocates for the Mentally Ill, 1996.

Certificate of Recognition, Mental Health Division, and State Division of Alcohol and Substance Abuse, Washington State, 1996.

Positive Role Model Nomination, 1997 Fourth Year Medical Class.

Ten Best Papers in America, 2000, “Alcohol interventions in a trauma center as a means of reducing the risk of injury reoccurrence,” Archives of Surgery, September, 1999.

Best Doctors in Seattle 2002, 2003. Distinguished Fellow, American Psychiatric Association, 2003. Fellow, American Society of Addiction Medicine, 2003. Best Doctors in America 1995-2013 Outstanding Community Psychiatrist Award- Washington State

Association of Community Psychiatrists 2008 Washington State Co-occurring Disorders Conference Outstanding

Service Award 2006 Outstanding Community Psychiatrist Award- Washington State

Association of Community Psychiatrists 2008

Board Certification:

Part I, American Board of Psychiatry and Neurology, 1981. Part II, American Board of Psychiatry and Neurology, 1982. Added Qualifications in Addiction Psychiatry, American Board of

Psychiatry and Neurology, 1993, recertified 2003. Board Certification #s: Psychiatry 23403; Addiction

Psychiatry Diplomate Number 358 Certification in Addiction Medicine, American Society of


3

Addiction Medicine, 1987. American Board of Addiction Medicine 2012

License to Practice:

State of Washington, MD 1976-current

Organizations: American Psychiatric Association, 1978-present, Fellow 1990, Distinguished Fellow, 2003-current.

American Society of Addiction Medicine, 1985-present., Fellow 2002

American Academy of Psychiatrists in Alcoholism and Addictions (AAPAA), 1985-current

Reviewer: Alcohol Health and Research World

American Journal of Addictions General Hospital Psychiatry Hospital and Community Psychiatry/Psychiatric Services International Journal of Psychiatry in Medicine Journal of Nervous and Mental Diseases Journal of the American Geriatric Society Journal of Studies on Alcohol Schizophrenia Bulletin American Journal of Drug and Alcohol Abuse Comprehensive Psychiatry Am Journal of Psychiatry

Special Local and National

Responsibilities:

Member, DSM-III Clinical Trials Task Force, American Psychiatric Association, 1977.

APA Work Group to Revise DSM-III, Affective Disorders Section, 1984.

Contributor APA: Case studies for DSM IIIR. APA, 1986 Contributor APA: Treatment Guidelines for Bipolar Disorder,

1994. Chair, Dual Diagnosis Committee, American Society of Addiction

Medicine, 1988-1992. Chair, Treatment Improvement Protocol on Dual Diagnosis, Center

for Substance Abuse Treatment, 1993-1994. Co-Chair, National Program Committee for American Academy of

Psychiatrists on Alcoholism and Addictions, 1992-1995, current member.

Advisory Group, National Institute on Drug Abuse for Development of Educational Videos around Drug Abuse, 1991-1995.

Selected as CPT code consultant, addictions and psychiatry, American Medical Association 1993.


4

Selected as co-chair, national Conference and Pre-Board Exam Course in Addictions Psychiatry, American Academy of Psychiatrists on Alcohol and Addictions 1993.

Member of the Governing Council of the Section for Psychiatric and Substance Abuse Services, American Hospital Association, 1993-1995.

Advisory Group, Center for Substance Abuse Treatment on Development of Treatment Improvement Protocols in the Area of Substance Abuse. 1995-current.

Advisory Group on New Research Agendas, Center for Substance Abuse Treatment, Washington, DC, 1996-current.

National Consultant, Substance Abuse Prevention and Treatment Block Grants (CSAT), 1995-current.

Co-Editor, Principles of Addiction Medicine, American Society of Addiction Medicine, 1998 2--3-Vol 2, 3

Editorial Board, American Journal on Addictions, 1999-current Editorial Board, CSAT Treatment Improvement Protocols, 2001-

current Chair, Steering Committee, Co-occurring Disorders Center of

Excellence (National Training Center Grant, CSAT, Sacks,S PI 2004-2008)

Co-chair, CSAT Treatment of Co-Occurring Alcohol-Drug and Mental Disorders, Treatment Improvement Protocol TIP 42, winner of APEX Publishers’ Award of Excellence, 2005.

Medical Director, Washington State Division of Alcohol and Substance Abuse, 2004- 2009

Medical Director, Washington State Department of Social and Health Services Mental Health Division, November 2006-September 2007

Editor , Principles of Addiction Medicine, American Society of Addiction Medicine Vol, IV 2009, and Vol V in process

Grants: P.I., Sleep and Mood Patterns in Arthritis Patients, Arthritis

Foundation, $1,736.25, 1981 (funded again, $900, 1982). P.I., Dual Diagnosis Intervention Study, NIDA, $301,450, January

1989-1993. P.I., Cost of Alcohol in Trauma Patients, Alcohol and Drug Abuse

Institute, $15,000, 1993. Co-P.I., Depression in Primary Care, Washington Institute, 5%,

$200,000, 1992-1994. Co-P.I., Alcohol Intervention in Trauma patients, NIAAA, 10%,

$1,028,000, 1993-1996. P.I., Contingent Benefits in Substance Abusing Mentally Ill,

NIDA, 20%, 1997-1999, $416,000. Co-P.I., Physician Skills in Alcohol Problem Intervention.


5

National Highway Traffic Safety Administration, 5%, $250,000, 1997-1999.

Co-investigator NIDA Clinical Trials Network, Donovan PI, NIDA 5%, $1,266,452, 2001 - ongoing

Co-investigator, Pharmacological and Behavioral Treatment with Alcoholics Donovan, PI, NIAAA, 1997 – 2003

Co PI (Linehan) Evaluation of DBT and Suboxone for Persons with combined Borderline PD and Opiate Dep, NIH/NIDA, 10%, $2,318,864, 2003-2009.

Co Investigator Consortium on the Genetics of Endophenotypes and Schizophrenia (Tsuang), NIH, 10%, $1,946,050, 2003.

Medical Director, Washington State Screening, Brief Intervention, and Referral for Treatment (WASBIRT) (Stark), CSAT, 10%, $16,100,000, 2003-2008

PI, Developing the Co-occurring Matrix Assessment Tool, CSAT, 20%, $200,000, 2004-2006.

PI, Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill, NIDA, 30%, $2,000,000, 9/30/2007-8/31/2011

PI, Preventing Addiction Related Suicide , NIDA, 15%, $750,000 4/2009 -2012

Co-investigator: Roy-Byrne, P: Brief Intervention for Drug Abuse in Primary Care 10% NIDA $2,000,000, 1/2009-14

Co PI (Comtois) Continuity Contacts via Text Message – Texting a brief intervention to prevent suicidal ideation and behavior, 10%, $1,200,000, 9/1/11-8/31/13

Co-I, Novel EtG Based Contingency Management for Alcohol in the Severely Mentally Ill, 7%, $675,000, 3/10/12-2/28/15

Co-I Optimizing PTSD Treatments (OPT Study): Examining role of preference in PTSD treatment 10% Zoellner Clinical Trials Phase 4 Clinical Trial – NIDA Office Based Use of Buprenorphine for IV Heroin Dependence Co-investigator – 12/99–2001 Phase 4 Clinical Trial – Bristol Myers – Squibb Efficacy of Serzone in Depression with Alcoholism Co-investigator - 1/96–98 - $100,000 Phase 3 Clinical Trial – Zeneca Pharmaceuticals Efficacy of Seroquel in Schizophrenia Co-investigator - 2/96–98 - $ 120,000 Phase 3 Clinical Trial – Pfizer Pharmaceuticals Efficacy of Ziprasidone in Schizophrenia Co-investigator - 7/95–97 - $150,000


6

Phase 3 Clinical Trial - Abbott Pharmaceuticals Safety and Efficacy of Sertindole in Schizophrenia Co-investigator 10/93–5/94 - $50,000 Phase 3 Clinical Trial - Eli Lilly Company Efficacy of Olanzapine in Schizophrenia Co-investigator - 6/92–12/93 - $1,000,000

Bibliography: Journal Articles

1. Ries, RK, Bokan JA: Electroconvulsive therapy following pituitary surgery. Journal of Nervous and Mental Disease 167(12):767-768, 1979.

2. Ries RK, Schuckit MA: Catatonia and autonomic hyperactivity. Psychosomatics 21(4):349-350, 1980.

3. Ries RK, Bokan JA, Kleinman A, Schuckit MA: Psychiatric consultation-liaison service: Patients, requests and functions. General Hospital Psychiatry 3:204-212, 1980.

4. Ries RK: DSM-III differential diagnosis of Munchausen’s syndrome. Journal of Nervous and Mental Disease 168(10): 629-632, 1980.

5. Ries RK, Bokan JA, Schuckit MA: Recognizing the drug abuser with psychiatric complaints. Behavioral Medicine 7(9):18-21, 1980.

6. Katon W, Ries RK, Bokan JA, Kleinman A: Hyperemesis gravidarum: A biopsychosocial perspective. International Journal of Psychiatry in Medicine 10(2):151-162, 1980.

7. Ries RK, Bokan JA, Schuckit MA: Modern diagnosis schizophrenia in hospitalized psychiatric patients. American Journal of Psychiatry 137(11): 1419-1421, 1980.

8. Ries RK, Hunt DD, Ward NG, Mason JC: Medical students and psychiatric inpatients: An encounter of the first kind. Journal of Medical Education 55:773-777, 1980.

9. Wilson L, Ries RK, Bokan JA: Transcultural psychiatry on an American inpatient psychiatric ward. Hospital and community Psychiatry 31(11):759-762, 1981.

10. Bokan, JA, Ries RK, Katon WJ: Tertiary gain and chronic pain. Pain 10(3):331-335, 1981.

11. Ries RK, Wilson L, Bokan JA, Chiles JA: ECT in medication resistant schizoaffective disorder. Comprehensive Psychiatry 22(2):167-173, 1981.

12. Ries RK, Bokan JA, Katon WJ, Kleinman A: The medical care abuser: Differential diagnosis and management. Journal of Family Practice 13(2):257-265, 1981.


7

13. Katon W, Williamson P, Ries RK: A prospective study of 60 consecutive psychiatric consultations in a family medicine clinic. Journal of Family practice 13(1):47-56, 1981.

14. Hunt DD, Dagadakis C, Ward NG, Ries RK: Live versus videotape interviews. Journal of Medical Education 56:916-918, 1981.

15. Ward NG, Strauss MM, Ries RK: The dexamethasone suppression test as a diagnostic aid in late onset paranoia. Journal of Nervous and Mental Disease 170:248-250, 1982.

16. Phillips M, Ward N, Ries RK: Factitious mourning: Painless patienthood. American Journal of Psychiatry 140(4):420-425, 1983.

17. Hall D, Ries RK: Bipolar illness, catatonia and the dexamethasone suppression test (DST) in adolescents. American Journal of Psychiatry 44(6):222-224, 1983.

18. Katon W, Ries RK: Schizophrenia: A clinical review. Journal of Family Practice 17(1):99-124, 1983.

19. Katon W, Ries RK, Kleinman A: Part I. The prevalence of somatization in primary care. Comprehensive Psychiatry 25(2):208-215, 1984.

20. Katon W, Ries RK, Kleinman A: Part II. A prospective DSM-III study of 100 consecutive somatization patients. Comprehensive Psychiatry 25(3):305-314, 1984.

21. Ries RK, Gilbert DA, Katon W: Tricyclic antidepressant therapy for peptic ulcer disease. Archives of Internal medicine 144(3):566-569, 1984.

22. Ries RK: Poor interrater reliability of MECTA EEG seizure duration measurement during ECT. Biological Psychiatry 20:94-119, 1985.

23. Ries RK: DSM-III implications of the diagnosis of catatonia and bipolar disorder. American Journal of Psychiatry 142(12):1471-1474, 1985.

24. Ries RK, Witkowsky AK: Synergistic action of alprazolam with tranylcypromine in drug resistant atypical depression with panic attacks. Biological Psychiatry 21(5-6):522-526, 1986.

25. Ries RK, Samson HH: Substance abuse among inpatient psychiatric patients: Clinical and training issues. Substance Abuse 8(2):28-34, 1987.

26. Vitiello MF, Prinz PN, Personius JP, Nuccio MA, Ries RK, Koerker RM: A history of chronic alcohol abuse is associated with increased nighttime hypoxemia in older men. Alcoholism: Clinical and Experimental Research 11(4):368-371, 1987.

27. Raskind MA, Courtney N, Murburn MM, Backus FI, Bokan JA, Ries RK, Dorsa DM, Weitzman RE: Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients. Biological Psychiatry 22:453-462, 1987.

28. Foster S, Ries RK: Delayed hypertension with ECT. Journal of Nervous and Mental Disease 176(6):374-376, 1988.

29. Williams DE, Vitiello MV, Ries RK, Bokan J, Prinz PE: Successful recruitment of elderly, community dwelling subjects for Alzheimer’s disease research: Cognitively


8

impaired, major depressive disorder and normal control groups. Journal of Gerontology, 143(3):M69-M74, 1988.

30. Ries RK: The future role of psychiatry in AMERSA. Substance Abuse 9:177-178, 1988.

31. Ries RK, Roy-Byrne PP, Ward NG, Neppe V, Cullison S: Carbamazepine treatment for benzodiazepine withdrawal. American Journal of Psychiatry, 146:536-537, 1989.

32. Ries RK: substance abuse intervention on inpatient psychiatry. Substance Abuse 10:28-32, 1989.

33. Nickoloff SE, Neppe VM, Ries RK: Factitious AIDS. Psychosomatics 30(3):342-345, 1989.

34. Vitiello MV, Prinz PN, Williams DE, Frommlet MS, Ries RK: Sleep disturbances in patients with mild-stage Alzheimer’s disease. Journal of Gerontology 45(4):M131-138, 1990.

35. Vitiello MV, Prinz PN, Avery DH, Williams DE, Ries RK, Bokan JA, Khan A: Sleep is undisturbed in elderly, depressed individuals who have not sought health care. Biological Psychiatry 27:431-440, 1990.

36. Ries RK, Ellingson T: A pilot assessment at one month of 17 dual diagnosis patients. Hospital and Community Psychiatry 41(11):1230-1233, 1990.

37. Miller NS, Ries RK: The role of recovering persons in medical education. Substance Abuse 1(12):42-47, 1991.

38. Ries RK, Mullen MA: Substance abuse: Clinical practicums in medical student education. Substance Abuse 1(12):42-47, 1991.

39. Miller NS, Ries RK: Drug and alcohol dependence and psychiatric populations: The need for diagnosis, intervention and training. Comprehensive Psychiatry 32(3):268-276, 1991.

40. Goldberg HI, Mullen M, Ries RK, Psaty B, Ruch BP: Alcohol counseling in a general medicine clinic: A randomized controlled trial of strategies to improve referral and show rates. Medical Care 29(7, Supplement):JS49-JS56, 1991.

41. Ries RK, Cullison S, Horn R, Ward N: Benzodiazepine withdrawal: Clinician’s ratings of carbamazepine treatment versus traditional taper methods. Journal of Psychoactive Drugs 23(1):73-76, 1991.

42. Rivara FP, Gurney JG, Ries RK, Seguin DA, Copass MK, Jurkovich GJ: A descriptive study of trauma, alcohol and alcoholism in young adults. Journal of Adolescent Health 13(8):663-667, 1992.

43. Cowley DS, Roy-Byrne PP, Godon C, Greenblatt DJ, Ries RK, Walker RD, Samson HH, Hommer DW: Response to diazepam in sons of alcoholics. Alcoholism: Clinical and Experimental Research 16(6):1057-1063, 1992.

44. Ries RK: Serial, parallel and integrated models of dual diagnosis treatment. Journal of Health Care for the Poor and Underserved 3(1): 173-180, 1992.


9

45. Ries RK: Clinical treatment matching models for dually diagnosed patients. Psychiatric Clinics of North America 16(1):167-175, 1993.

46. Jurkovich GJ, Rivara FP, Gurney JG, Fligner C, Ries RK, Mueller BA, Copass M: The effect of acute alcohol intoxication and chronic alcohol abuse on outcome from trauma. Journal of the American Medical Association 270(1):51-56; 93-94, 1993.

47. Ries RK: The dually diagnosed patient with psychotic symptoms. Journal of Addictive Diseases 12(3):103-122, 1993.

48. Rivara FP, Jurkovich GJ, Gurney JG, Seguin D, Fligner CL, Ries RK, Raisys VA, Copass M: The magnitude of acute and chronic alcohol abuse in trauma patients. Archives of Surgery 128(8):907-913, 1993.

49. Decker K, Ries RK: Differential diagnosis and psychopharmacology of dual disorders. Psychiatric Clinics of North America 16(4):703-718, 1993.

50. Roy-Byrne P, Sullivan M, Cowley D, Ries RK: Adjunctive treatment of benzodiazepine discontinuation syndromes: A review. Journal of Psychiatric Research 27(Suppl 1):143-153, 1993.

51. Ries RK, Mullen M, Cox G: Symptom severity and utilization of treatment resources among dually diagnosed inpatients. Hospital and Community Psychiatry 45(6):562-568, 1994.

52. Comtois K, Ries RK, Armstrong H: Case manager ratings of the clinical status of dually diagnosed outpatients. Hospital and Community Psychiatry 45(6): 568-573, 1994.

53. Nilssen O, Ries RK, Rivara FP, Gurney J, Jurkovich J: The CAGE and SMAST in trauma patients: The comparison of their correlation with biological alcohol markers. Journal of Trauma 36(6): 784-788, 1994.

54. Comtois K, Ries RK: Sex differences in dually diagnosed severely mentally ill clients in dual diagnosis outpatient treatment. American Journal on Addictions 4(3):245-253, 1995.

55. Roy-Byrne P, Dagadakis C, Ries R, Decker K, Jones R, Bolte MA, Scher M, Brinkley J, Gallagher M, Patrick DL, Mark H: I. A psychiatrist-rated battery of measures for assessing the clinical status of psychiatric inpatients. Psychiatric Services 46:347-352, 1995.

56. Tsuang D, Cowley D, Ries R, Dunner DL, Roy-Byrne P: The effects of substance use disorder on the clinical presentation of anxiety and depression in an outpatient psychiatric clinic. Journal of Clinical Psychiatry 56(12):549-555, 1995.

57. Nilssen O, Ries RK, Rivara FP, Gurney J, Jurkovich J: The WAM score: Sensitivity and specificity of a user friendly biological screening test for alcohol problems in trauma patients. Addictions 91(2):255-262, 1996.

58. Nilssen O, Ries RK, Rivara FP, Gurney JG, Jurkovich GJ: Alcohol and trauma: the impact of acute and chronic alcohol abuse on injury severity and death in a trauma population. Norsk Epidemiologi 6(1): 103-108, 1996.


10

59. Roy-Byrne P, Dagadakis C, Unitzer J, Ries R: Evidence for limited validity of the revised GAF/SOFAS. Psychiatric Services, 47:864-866, 1996.

60. Dunn CW, Ries R: Linking substance abuse services with general medical care: Integrated, brief interventions with hospitalized patients. American Journal of Drug and Alcohol Abuse, 23(1):1-13, 1997.

61. Russo J, Roy-Byrne P, Jaffe C, Ries R, Dagadakis C, Reeder D. The relationship of patient-administered outcome assessments to quality of life and physician ratings: Validity of the BASIS-32. Journal of Mental Health Administration. 24(2):200-214, 1997.

62. Russo J, Roy-Byrne P, Reeder D, Alexander M, Dwyer-O’Connor E, Dagadakis C, Ries R, Patrick D: Longitudinal assessment of quality of life in acute psychiatric inpatients: Reliability and validity. Journal of Nervous and Mental Disease 185(3):166-175, 1997.

63. Ries R, Comtois K, Roy-Byrne PP: Illness severity and treatment services for dually diagnosed severely mentally ill outpatients. Schizophrenia Bulletin 23(2):239-246, 1997.

64. Ries R, Dyck D: An examination of representative payee practices of community mental health centers in Washington State. Psychiatric Services 48(6):811-814, 1997.

65. Pirzada S, Ries RK, LoGerfo J: Cost of comorbid alcohol and drug problems. American Journal on Addictions 6(3):193-204, 1997.

66. Ries R, Comtois KA: Managing disability benefits as part of treatment for persons with severe mental illness and co-morbid drug/alcohol disorders: A comparative study of payee and non-payee participants. The American Journal on Addictions 6(4):330-338, 1997.

67. Pages K, Russo J, Roy-Byrne P, Ries R, Cowley D: Determinants of suicidal ideation: The role of substance use disorders. Journal of Clinical Psychiatry, 58 (11):510-515, 1997.

68. Russo J, Roy-Byrne P, Jaffe C, Ries R, Dagadakis C, Avery D: Psychiatric status, quality of life, and level of care as predictors of outcomes of acute inpatient treatment. Psychiatric Services 48(11):1427-1434, 1997.

69. Avery DH, Bolte MA, Ries R: Dawn simulation treatment of abstinent alcoholics with winter depression. Journal of Clinical Psychiatry 59(1):36-42, 1998.

70. Pages KP, Ries RK: Use of anticonvulsants in benzodiazepine withdrawal. American Journal on Addictions 7(3):198-204, 1998.

71. Russo J, Trujillo CA, Wingerson DK, Decker K, Ries R, Wetzler H, Roy-Byrne PP: The MOS 36-item short-form health survey (SF-36): reliability, validity and preliminary findings in schizophrenic outpatients. Medical Care 36(5): 752-756, 1998.


11

72. Roy-Byrne P, Russo J, Rabin L, Fuller K, Jaffe C, Ries R, Dagadakis C, Avery D: A brief medical necessity scale: Reliability, validity and clinical utility. Journal of Behavioral Health Services and Research 25:412-424, 1998.

73. Pages K, Russo J, Wingerson D, Ries R, Roy-Byrne P, Cowley D: Predictors and outcome of against medical advice (AMA) discharges in the psychiatric units of a general hospital. Psychiatric Services 49:1187-1192, 1998.

74. Wingerson D, Ries R: Assertive Community Treatment for patients with chronic and severe mental illness who abuse drugs. Journal of Psychoactive Drugs 31(1):13-18, 1999.

75. Ries RK, Jaffe C, Comtois K, Kitchell M: Patient satisfaction and outcome with integrated dual diagnosis treatment. Community Mental Health Journal 35(3):213-221, 1999.

76. Gentilello LM, Villaveces A, Ries R, Nason KS, Daranciang E, Donovan DM, Copass M, Jurkovich GJ, Rivara FP. Detection of acute alcohol intoxication and chronic alcohol dependence by trauma center staff. Journal of Trauma 47(6):1131-1139, 1999.

77. Gentilello LM, Rivara FP, Donovan DM, Jurkovich GJ, Daranciang E, Dunn CW, Villaveces A, Copass M, Ries RR: Alcohol interventions in a trauma center as a means of reducing the risk of injury recurrence. Annals of Surgery 230(4):473-483, 1999.

78. Ries, R.K., Russo, J., Wingerson, D., Snowden, M., Comtois, K.A., Srebnik, D., Roy-Byrne, P.P. Shorter hospital stays and more rapid improvement among patients with schizophrenia and substance disorders. Psychiatric Services 51:210-215, 2000.

79. McCann BS, Simpson TL, Ries R, Roy-Byrne P. Reliability and validity of screening instruments for drug and alcohol abuse in adults seeking evaluation for Attention-Deficit/Hyperactivity Disorder. The American Journal on Addictions 9:1-9, 2000.

80. Gentilello LM, Rivara FP, Donovan DM, Villaveces A, Daranciang E, Dunn CW, Ries R. Alcohol problems in women admitted to a Level I Trauma Center: A gender-based comparison. The Journal of Trauma: Injury, Infection, and Critical Care 48(1):108-114, 2000.

81. Roy-Byrne P., Pages K, Russo J, Blume A, Jaffe C, Kingsley E, Cowley D, Ries R,: A double blind, placebo controlled trial of nefazodone in the treatment of major depression in alcohol dependent subjects. Journal of Clinical Psychopharmacology 20(2):129-136, 2000.

82. Wingerson D, Russo J, Ries R, Dagadakis C, Roy-Byrne P. Use of psychiatric emergency services and enrollment status in a public managed mental health care plan. Psychiatric Services 52(11):1494-1501, 2001.

83. Ries RK, Demirsoy A, Russo JE, Barrett J, Roy-Byrne PP. Reliability and clinical utility of DSM-IV Substance-Induced Psychiatric Disorders in acute psychiatric inpatients. American Journal on Addictions 10:308-318, 2001.


12

84. Ries R, Dyck D, Short R, Srebnik D, Snowden M, Comtois KA. Use of case manager ratings and weekly urine toxicology tests among outpatients with dual diagnoses. Psychiatric Services 53(6):764-766, 2002.

85. Srebnik D, Comtois KA, Stevenson J, Hoff H, Snowden M, Russo J, Ries RK. Eating disorder symptoms among adults with severe and persistent mental illness. Eating Disorders: The Journal of Treatment and Prevention, 11(1):27-38, 2003.

86. Hendryx MS, Russo JE, Stegner B, Dyck D, Ries R, Roy-Byrne P. Predicting rehospitalization and outpatient services from administration and clinical databases. Journal of Behavioral Health Services and Research 30(3):342-351, 2003.

87. Ferguson L, Ries R, Russo J. Barriers to identification and treatment of hazardous drinkers as assessed by urban/rural primary care doctors. Journal of Addictive Diseases 22(2):79-90, 2003.

88. Comtois KA, Russo J, Snowden M, Srebnik D, Ries R, Roy-Byrne P. Factors associated with high use of public mental health services by persons with Borderline Personality Disorder. Psychiatric Services 54(8):1149-1155, 2003.

89. Dunn C., Zatzick D, Russo J, Rivara F, Roy-Byrne P, Ries R, Wisner D, Gentilello L. Hazardous drinking by trauma patients during the year after injury. Journal of Trauma; 54(4):707-712, 2003.

90. Minkoff K, Zweben J, Rosenthal R, Ries R. Development of service intensity criteria and program categories for individuals with co-occurring disorders. J Addict Dis, 22 Suppl 1:113-129, 2003.

91. Comtois KA, Russo JE, Roy-Byrne PP, Ries RK. Clinicians' assessments of bipolar disorder and substance abuse as predictors of suicidal behavior in acutely hospitalized psychiatric inpatients. Biol Psychiatry, 56:757-763, 2004.

92. Ries RK, Short RA, Dyck DA, Srebnik D, Fisher A, Snowden M, Comtois KA. Outcomes of Managing Disability Benefits in Substance Dependent Severely Mentally Ill Patients. Psychiatric Services, 55(4):445-447, 2004.

93. Donovan DM, Dunn CW, Rivara FP, Jurkovich GJ, Ries RR, & Gentilello LM. Comparison of trauma center patient self-reports and proxy reports on the Alcohol Use Identification Test (AUDIT). Journal of Trauma, 56(4):873-882, 2004.

94. Ries RK, Short RA, Dyck DG, Srebnik DS. Unlinking disability income, substance use, and adverse outcomes in dually diagnosed severely mentally ill outpatients. Am J Addictions, 13(4):390-397, 2004.

95. Erinoff L, Anthony JC, Brown GK, et al. Overview of workshop on drug abuse and suicidal behavior. Drug and Alcohol Dependency, 76 Suppl:S3-9, 2004.

96. Snowden M, Walaszek A, Russo JE, Comtois KA, Srebnick D, Ries RK. Geriatric patients improve as much as younger patients from hospitalization on general psychiatric units. Journal of the American Geriatrics Society, 52:1676-1680, 2004.

97. Ries RK. Co-occurring Alcohol Use and Mental Disorders. J Clin Psychopharmacol, 26(6 Suppl 1):S30-36, 2006.


13

98. Pasic J, Russo JE, Ries RK, Roy-Byrne PP. Methamphetamine users in the psychiatric emergency services: a case-control study. Am J Drug Alcohol Abuse 33(5):675-686, 2007.

99. Ries RK, Yuodelis-Flores C, Comtois KA, Roy-Byrne PP, Russo JE. Substance induced suicidal admissions to an acute psychiatric service: Characteristics and outcomes. J Subst Abuse Treat, 34(1):72-79, 2008.

100. Yen CF, Hsaio RC, Ries R, Liu SC, Huang CF, Chang YP, Yu ML. Insight into alcohol-related problems and its associations with severity of alcohol consumption, mental health status, race, and level of acculturation in Southern Taiwanese indigenous people with alcoholism. Am J Drug Alcohol Abuse 34(5):553-61, 2008.

101. Ries RK, Yuodelis-Flores C, Roy-Byrne PP, Nilssen O, Russo J. Addiction and suicidal behavior in acute psychiatric inpatients. Comprehensive Psychiatry 50:93-99, 2009.

102. McDonell MG, Comtois KA, Voss WD, Morgan AH, Ries R. Global Appraisal of Individual needs Short Screener (GSS): Psychometric Properties and Performance as a Screening Measure in Adolescents. Am J Drug Alcohol Abuse, 35(3):157-160, 2009.

103. Bell R, Farmer S, Ries R, Srebnik D. Metabolic risk factors among Medicaid

outpatients with schizophrenia receiving second-generation antipsychotics. Psychiatric Services 60:1686–1689, 2009.

104. Krupski, A., Sears, J.M., Joesch, J.M., Estee, S., He, L., Dunn, C., Huber, A.,

Roy-Byrne, P., Ries, R. (2010). Impact of brief interventions and brief treatment on admissions to chemical dependency treatment. Drug and Alcohol Dependence. 110 (1-2): 126-36.

105. Sears, J.M., Krupski A., Joesch, J.M., Estee, S.L., He, L., Shah, M.F., Huber, A., Dunn, C., Ries, R., Roy-Byrne, P.P. (2010). The use of administrative data as a substitute for individual screening scores in observational studies related to problematic alcohol or drug use. Drug and Alcohol Dependence. 111 (1-2): 89-96.

106. McDonell, M.G., Angelo, F., Sugar, A., Rainey, C., Srebnik, D., Short, R., Roll, J. Ries, R.K. (2011). Accuracy of onsite immunoassay urinalysis of illicit drug use in outpatients with co-occurring drug addiction and serious mental illness. The American Journal of Drug and Alcohol Abuse. 37 (2): 137-40.

107. McDonell, M.G., Howell, D., Srebnik, S., Angelo, F., Sugar, A.M., Rainey, C., Roll, J., Short, R., Ries, R. (2011). Evaluation of ethyl glucuronide immunoassay urinalysis in 5 alcohol dependent outpatients. The American Journal on Addictions.

108. Ries R, Wolitzky-Taylor KB, Operskalski JT, Craske MG, Roy-Byrne P. Treatment of comorbid substance use and anxiety disorders: a case study. J Addict Med, 5(4):248-253, 2011.


14

109. Wolitzky-Taylor K, Operskalski JT, Ries R, Craske MG, Roy-Byrne P. Understanding and treating comorbid anxiety disorders in substance users: review and future directions. J Addict Med, 5(4):233-47, 2011.

110. McDonell, M.G., Kaufman, E.K., Srebnik, D.S., Ciechanowski, P.S. & Ries, R.K. Barriers to Metabolic care for adults with serious mental illness: Provider perspectives. The International Journal of Psychiatry in Medicine. 4, 379-387, 2011.

111. Kaufman, E.K., McDonell, M.G., Cristofalo, M.A., & Ries, R.K. Barriers and solutions to metabolic syndrome management for the severely mentally ill: Patient and provider accounts. Issues in Mental Health Nursing, 33, 172-180, 2012.

112. McDonell, M.G., Howell, D.N., McPherson, S., Cameron, J.M., Srebnik, D., Roll, J.M., Ries, R.K. Investigation of the efficacy of voucher-based contingent reinforcement for alcohol abstinence, using the ethyl-glucuronide alcohol biomarker. Journal of Applied Behavior Analysis, 45, 161-165, 2012.

113. McDonell, M.G., Kerbrat, A.H., Comtois, K.A., Russo, J., Lowe, J.M., & Ries, R.K. Validation of the co-occurring disorder quadrant model. Journal of Psychoactive Drugs, 44, 266-273, 2012.

114. Srebnik, D., Sugar, A., Coblentz, P., McDonell, M.G., Angelo, F., Lowe, J.M., Ries, R.K., & Roll, J.M. Acceptability of contingency management among clinicians and clients within a co-occurring mental health and substance use treatment program. American Journal on Addictions, (In Press).

115. McDonnel MG, Srebnik …Ries R: Randomized Controlled Trial of Contingency Management for Stimulant Use in Community Mental Health Patients with Serious Mental Illness: (Am J Psychiatry 2013; 170:94–101)

116. Voss, WD, Kaufman, E., Connor, S.S., Comtois, K.A., Conner, K.R., Ries, R.K. Preventing Addiction Related Suicide: A Pilot Study. Journal of Substance Abuse Treatment: In press

Book Chapters:

1. Ries RK: Alcoholism and anxiety. In Roy-Byrne P (Ed.), Anxiety: New Findings for the Clinician (pp. 123-148). Washington DC: APA Press, 1988.

2. Ries RK, Miller NS: Dual diagnosis: Concept, diagnosis and treatment. In Dunner DL (ed.), Current Psychiatric Therapy (pp. 131-138). Philadelphia: W.B. Saunders, 1993.

3. Ries RK: Dual Disorders: The Psychotic Patient. In Miller NS (ed.), Principles of Addiction Medicine, Baltimore: American Society of Addiction Medicine, 1994.

4. Murray R, Ries RK: Treatment of addiction and psychotic disorders. In Miller N, Gold M, Smith D (eds.), Manual of Therapeutics for Addictions, Wiley-Liss, 1997.

5. Ries RK, Sloan K, Miller N: Dual diagnosis: Concept, diagnosis and treatment. In Dunner D (ed.), Current Psychiatric Therapy, pp 173-180. Philadelphia: Saunders, 1997.


15

6. Ries R: Managed care and dual diagnosis: Who, what, where, why, and how much care? Monograph. In Kassebaum P. (ed.) TIE Communique. Chevy Chase, MD: The CDM Group, 1998.

7. Goldsmith J, Ries R: Substance Induced Mood Disorders. In Principles of Addiction Medicine Vol III, Chevy Chase: American Society of Addiction Medicine, 2003.

8. Tidey JW, Ries RK: People with Mental Illness. In Higgins ST, Silverman K, Heil SH (eds.) Contingency Management in Substance Abuse Treatment. New York: The Guilford Press, 2008.

9. Ries RK, Galanter M, Tonigan JS: Twelve-Step facilitation: An adaptation for psychiatric practitioners and patients. In American Psychiatric Publishing Textbook of Substance Abuse Treatment. Arlington VA: American Psychiatric Publishing Inc, 2008.

10. Yuodelis-Flores C, Bennett M, Veitengruber J, Ries RK. Treatment of co-occurring disorders. In Ovsiew F and Munich R (eds.), Principles of Inpatient Psychiatry. Baltimore MD: Lippincott Williams & Wilkins, 2008.

11. Yuodelis-Flores C, Bennett WM, Meredith C, Ries RK. Addictions in Psychiatric Medicine. In Miller N and Gold M eds. Addictions in Medicine: Principles and Practices. London: John Wiley & Sons Ltd, 2008.

12. Pasic J, Ries R. Treatment of methamphetamine addiction that co-occurs with serious mental illness. In Roll JM, Rawson RA, Ling W, Shoptaw S eds. Methamphetamine Addiction: From Basic Science To Treatment, pp 230-245. New York: The Guilford Press, 2009.

13. Nunes EV, Selzer J, Levounis P, Davies CA (eds), Substance Dependence and Co-Occurring Psychiatric Disorders: Best Practices for Diagnosis and Clinical Treatment. Kingston NJ: Civic Research Institute, 2010.

Books, Videos, etc.:

1. Assessment and Treatment of Patients with Coexisting Mental Illness and Alcohol and Other Drug Abuse Treatment Improvement Protocol (TIP) Series, Number 9. R Ries (ed.). Washington D.C.: Center for Substance Abuse Treatment, 1994.

2. Dual Disorders. 1992. Co-author and participant. Washington, D.C.: National Institute on Drug Abuse. Videocassette.

3. Dual Disorders 101 - Basic Issues. 1996. Developer, author, participant, with Lurie H. Washington Institute for Mental Illness Research and Training. Videocassette.

4. Dual Disorders 102: Group Techniques. 1996. Developer, author, participant with Lurie H. Washington Institute for Mental Illness Research and Training. Videocassette.


16

5. Principles of Addiction Medicine, Volume III, AW Graham, TK Schultz, MF Mayo-Smith, RK Ries, BB Wilford (eds.). American Society of Addiction Medicine, Chevy Chase, 2003.

6. Substance Abuse Treatment for Persons with Co-Occurring Disorders. A Treatment Improvement Protocol TIP 42. S Sacks and R Ries (eds.) DHHS Publication No. (SMA)05-3992. US Department of Health and Human Services, Rockville MD, 2005.

7. Psychotherapeutic Medications 2006: What every Counselor Should Know, Ries R Co-editor, Mid America Addiction Technology Transfer Center, Kansas City Missouri, 2006.

8. Psychotherapeutic Medications 2008: What every Counselor Should Know, Ries R Contributing Editor, Mid America Addiction Technology Transfer Center, Kansas City Missouri, 2008.

Letters to the Editors:

1. Phillips M, Ward NC, Ries RK: Factitious mourning: Painless patienthood. Letter to editor (response). American Journal of Psychiatry 14(1):121, 1983.

2. Ries RK: Catatonia and bipolar disorder. Letter to editor, American Journal of Psychiatry 44:834-835, 1987.

3. Ries RK: Health Risk factors in adolescence: What about substance abuse? Letter to editor, Western Journal of Medicine 147(1):86, 1987.

4. Ries RK: Incentives can help hospitals to better address substance abuse. American Hospital Association News, November 1992.

Abstracts and Reviews:

1. Ries RK, Bokan JA: Electroconvulsive therapy following pituitary surgery. Abstract, Psychiatry Audit Digest, 1980.

2. Ries RK: DSM-III differential diagnosis of Munchausen’s syndrome. Abstract, Psychiatry News, 1983.

3. Phillips M, Ward NG, Ries RK: Factitious mourning: Painless patienthood. Abstract, Psychiatry Digest, 1983.

4. Ries RK, Gilbert DA, Katon W: Tricyclic antidepressant therapy for peptic ulcer disease. Abstract, Modern Medicine Abstracts, 1984.

5. Ries RK, Gilbert DA, Katon W: Tricyclic antidepressant therapy for peptic ulcer disease. Drug Newsletter, June, 1984.

6. Ries RK: ECT for health professionals. Review of teaching videotape, Hospital and Community Psychiatry, February, 1987.

7. Ries RK: ECT for patients and families. Review of teaching videotape, Hospital and Community Psychiatry, February, 1987.

8. Ries RK: Shock therapy: 20/20 documentary. Review of teaching videotape, Hospital and Community Psychiatry, February, 1987.


17

9. Miller NS, Ries RK: Substance dependence in psychiatric patients. Abstract, APA Annual Meeting, May 11-16, 1991.

10. Jurkovich GJ, Rivara FP, Gurney JG, Ries RK, Raisys VA, Copass MD: The magnitude of acute and chronic alcohol abuse in trauma patients. Western Surgical Association Annual Meeting, San Antonio, TX, November, 1992.

Selected Presentations: Invited Presentations at Academic Center Grand Rounds 1. Depression, Atypical Depression and Their Treatment. Psychiatric Grand Rounds,

Loyola, Chicago, 1988.

2. Depression, Atypical Depression: new Pharmacological Strategies. Psychiatry Grand Rounds, University of Oregon, Portland, April, 1990.

3. Dual Disorders: Concept and Diagnosis. Psychopharmacology Grand Rounds and two-day site visit, University of Michigan, Ann Arbor, February, 1992.

4. Dual Disorders: Special Issues of Psychopharmacology. Special Presentation, Kaiser Health Care, Oakland, CA, February, 1992.

5. Medications in Dually Disordered Patients. Psychiatry Grand Rounds, University of Texas, San Antonio, October, 1992.

6. Dual Disorder Treatment and Research. Department of Psychiatry, Tromso, Norway, October 1994.

7. Outcome in Severely Mentally Ill Dually Diagnosed Patients. Grand Rounds, Department of Psychiatry, University of Connecticut, May, 1995.

8. Treatment and Outcomes in SMI Dually Disordered. Special Rounds, McClean Hospital, Harvard Medical School, Boston, June, 1995.

9. Treatment and Outcome in Dual Disorders. Invited Workshop and Grand Rounds, University of Calgary, Alberta, June, 1995.

10. “Health Services Research in a Public Program for Severely Mentally Ill Dually Disordered Patients” Grand Rounds, Department of Psychiatry, University of South Carolina at Charleston, Charleston, SC, February 6, 1996.

11. Diagnosis and Treatment Issues in Dual Disorders. Grand Rounds, University of Oklahoma Health Sciences Center, Department of Psychiatry, Tulsa, Oklahoma, December 1997.

12. Dual Diagnosis Treatment Models. Invited Grand Rounds, University of California/San Francisco General, Department of Psychiatry, April 1998.

13. Analysis of In- and Outpatient Treatment Programs for Severe Dual Disorders. Grand Rounds presented for UCSD Department of Psychiatry at the VA Medical Center, San Diego, California, June, 1998.

14. Dual Diagnosis. Psychiatric Grand Rounds, Temple University Hospital, Philadelphia, September 1998.


18

15. Dual Diagnosis Treatment in SMI Populations, University of California at San Diego, VA Hospital Grand Rounds, October 1998.

16. Dual Diagnosis. Psychiatric Grand Rounds, University of Hawaii, Honolulu, November 1998.

17. Dual Diagnosis Treatment Models. Psychiatric Grand Rounds, University of Michigan, November 1998.

18. Outcomes for Dual Diagnosis Patients in Community Mental Health Settings, UC Davis Medical Center, Sacramento, California, October 1999.

19. Inpatient and Outpatient Dual Diagnosis Models of Treatment and Outcomes, Robert Wood Johnson Medical School, Piscataway, New Jersey, November, 1999.

20. Treatment of Severely Mentally Ill Dual Disorder, University of Connecticut, June, 2001

21. Representative Payee Interventions in Dual Disorders, Yale, June 2001.

22. Representative Payee Interventions, Montefiori Hospital, New York, New York, November 2003.

23. Suicide and Addictions (Grand Rounds); Visiting Professor in Addictions: University of Hawaii, Honolulu, May 2004

24. Medications of Co-occurring Disorders, University of Hawaii, Trippler Army Hospital. Mar 2005

25. Relapse Prevention Medications; Cedars Sinai Dept of Psychiatry, Los Angeles, Feb 2006

26. Relapse Prevention Medications; Dept Internal Medicine, University of Hawaii, Mar 2006

27. Relapse Prevention Medications; Dept Internal Medicine, University of Hawaii, Feb 2007

Presentations at National and International, Recent State and Regional Meetings 1. Live vs. Videotape Interviews. American Psychiatric Association Annual Meeting,

New Orleans, May 12, 1981 (Hung, Ward, Dagadakis, Ries).

2. Factitious Mourning: Painless Patienthood. American Psychiatric Association Annual Meeting, Toronto, May 21, 1982 (Phillips, Ward, Ries).

3. Reliability of EEG Seizure Duration During ECT. Society of Biological Psychiatry, Los Angeles, may, 1984.

4. Catatonia and Affective Disorder. Work Group to Revise DSM-III, New York, April, 1984.

5. Irritable Bowel Syndrome. Section Leader, Depression and Chronic Disease Symposium, San Diego, 1985.

6. Substance Abuse Among Psychiatric Residents. Association for Medical Education and Research in Substance Abuse, Washington, DC, 1986.


19

7. Adolescent Substance Abuse. Today’s Youth--Tomorrow’s Future, Symposium, Salt Lake City, 1987.

8. Dual Diagnosis Inpatient Unit. Association for Medical Education and Research in Substance Abuse, Washington, DC, 1987.

9. Current Trends in Treating Depression. Hospital and Community Psychiatry, New Orleans, October, 1988.

10. Dual Diagnosis. Plenary Session, Hospital and Community Psychiatry Convention, Philadelphia, October, 1989.

11. Carbamazepine for Benzodiazepine Withdrawal. Association for Medical Education and Research in Substance Abuse, Washington, DC, November, 1989.

12. Medical Student Teaching in Substance Abuse: Model Program. AMERSA, Washington, DC, November, 1989.

13. Anxiety and Depressive Disorders. Symposium on Dual Disorders, American Society of Addiction Medicine, Phoenix, April, 1990.

14. Substance Abuse Intervention on Psychiatric Inpatient Units. NIDA National Conference on Drug Abuse Research and Practice, Washington, DC, January, 1991.

15. Psychiatric Medications in Recovery: Help or Hindrance? Twenty-second Annual Medical-Scientific Conference, American Society of Addiction Medicine, National Convention, Boston, April, 1991.

16. Alcohol, Drugs and the Health Care System. Invited Lecturer, National Conference, Meharry Medical College, Nashville, TN, October, 1991.

17. Integrating CD Counselors Into Teaching Hospital medical/Surgical/Psychiatric Services. AMERSA (Association for Medical Education and Research in Substance Abuse), Bethesda, MD, November, 1991.

18. Substance Use Disorders and Anxiety Disorders. Invited Lecturer, National Conference, American Academy of Psychiatrists on Alcoholism and Addiction, December, 1991.

19. Dual Disorders: Conceptual issues. American Society of Addiction Medicine, Washington, DC, March, 1992.

20. Benzodiazepines: Use, Abuse, Dependence, Special Pharmacological Issues. American Society of Addiction Medicine Convention, Washington, DC, March, 1992.

21. Dual Diagnosis. Plenary Session, American Academy of Psychiatrists on Alcohol and Addiction National Conference, Tucson, December, 1992.

22. Dual Diagnosis in a Severely Mentally Ill Outpatient Population. State Conference on Alcohol and Substance Abuse, Department of Alcohol and Substance Abuse, Olympia, WA, May, 1993.

23. Assessment of Acute Dual Diagnosis Inpatients. College on Problems of Drug Dependency National Conference, Toronto, Canada, June, 1993.


20

24. Development and Establishment of a Dual Diagnosis Program for Severely Mentally Ill Patients. Technology Transfer Conference, National Institute of Drug Abuse National Conference, Washington, DC, July, 1993.

25. Dual Diagnosis: Definition, Diagnosis, and Intervention. Workshop, national Conference of American Society of Addiction Medicine, Orlando, FL, October, 1993.

26. Outcome measurement in Severe Mental Illness. Presented to hospital administrators, staff, researchers of American Hospital Association, Washington, DC, June, 1994.

27. Dual Disorder Treatment, Dual Disorder Managed Care. State directors of substance abuse for U.S. and territories, at Center for Substance Abuse Treatment National Conference, Seattle, WA, December 1994/

28. Harm Reduction Approaches in the Dually Diagnosed. Harm Reduction National Conference invited speaker, Seattle, WA, January, 1995.

29. Dual Disorder in the Severely Mentally Ill. American Society of Addiction Medicine, National Conference, Chicago, April, 1995.

30. Outcomes in SMI Dually Disordered: Does Severity of Illness Match Intensity of Services?” Invited Speaker, Faulkenberg Medical Outcomes Conference, Boston, June, 1995.

31. Integrated Treatment for Dual Disorders and Defining Elements of Long-term Treatment. Invited Plenary Speaker, Seventh Annual Conference on Persons with Mental Illness and Substance Abuse, Medical College of Pennsylvania, September 1995.

32. Improving Services: Co-occurring Substance Abuse and Mental Health Disorders. For Center for Substance Abuse Treatment National Conference, Georgetown University, Washington DC. Sponsored by Center for Substance Abuse Treatment. November 13-14, 1995

33. Use of the Representative Payee Mechanism as Contingency Management in the Treatment of Severely Mentally Ill Dually Disordered Patients. At the National Meeting College on Problems of Drug dependency, San Juan Puerto Rico. June 30, 1996.

34. Dual Diagnosis. AMTA International Methadone Conference, Chicago, Illinois. April 14, 1997.

35. PsychLink: National Television Program on Dual Disorder. Wescot Communications, Dallas, Texas. May 7, 1997.

36. Stages of Treatment and Relapse Response. Presented to Treatment Professionals of the National Football League, Burlington, Vermont, October 1997.

37. Substance Abuse Issues in Schizoaffective Disorder. Presented at the Fourth Annual Resident Education Conference of the Chicago Consortium for Psychiatric Research, Washington, DC, October 1997.


21

38. Use of Anticonvulsants in the Treatment of Substance Use Disorders. Roundtable at the American Academy of Addiction Psychiatry, Annual Meeting, San Antonio, Texas, December, 1997.

39. Co-Occurring Disorders: Strategies for effective Interventions. Plenary Session of the National Conference on Mental Health Statistics, Washington, D.C., May 1998.

40. Illness Severity and Diagnosis Matching Service Intensity in Intensive Outpatient Program for SPMI with PSUD. Presented at Psychiatric Services, Los Angeles, October 1998.

41. Dual Diagnosis: Schizophrenia and Substance Abuse. Presented at American Association of Addiction Psychiatry Annual Meeting, Amelia Island, Florida, December 1998.

42. Treatment of Chronically Mentally Ill Substance Users, presented at the American Society of Addiction Medicine’s 30th Annual Medical-Scientific Conference, New York, May 1999.

43. Contingent Management of Disability Benefits Improves Substance Abuse in the Severely Mentally Ill, at CPDD, Acapulco, June, 1999

44. Decreased Hospital Length of Stay and More Rapid Symptomatic Improvement in Acute Dual vs. Non-dually Diagnosed Schizophrenia, at AAAP, Nassau, December, 1999.

45. Clinicians at Work. American Academy of Addiction Psychiatry National Meeting, December, 2001.

46. Alcohol and Trauma. Center for Disease Control National Workgroup, Virginia, 2001.

47. Substance Induced Mood Disorders and Community Mental Health: Center for Mental Health Services Statistics Conference, Washington, DC, May 2002.

48. Onsite vs. Offsite Psychiatric Services in Addiction Treatment: Clinical Trials Network National Meeting, Seattle, August 2002.

49. Addiction and Suicide: NIDA Special Invitation Conference, Washington DC, March 2003.

50. Addiction and Suicide CSAT Section: College on Problems of Drug Dependency, Miami, June 2003.

51. Contingent Disability Benefits in Severe Dual Disorders: California Society of Addiction Medicine, San Francisco, October 2003.

52. Integrated treatment for co-occurring disorders: California Society of Addiction Medicine, October 2003

53. Medication, Metabolics and Dual Disorders Conditions: Washington State Alliance for the Mentally Ill, Seattle, October 2003.


22

54. Addictions and Suicide: American Society of Addiction Medicine State of the Art Conference, Washington DC, October 2003

55. Addictions, Bipolar, and Suicide: National Depression and Bipolar Support Alliance, Washington DC, November 2003.

56. 12-Step Facilitation for Psychiatrists: American Academy of Addiction Psychiatrists, New Orleans, December 2003.

57. Addiction and Suicide: NIDA Symposium, Washington DC, January 2004.

58. 12-Step Facilitation for Physicians: Washington State Society of Addiction Medicine, Seattle, February 2004.

59. The Co-occurring Matrix: Western States Addiction Directors, Ka Nee Ta, Oregon, April 2004.

60. Suicide and Addiction, NIDA Symposium: American Psychiatric Association, New York City, May 2004.

61. Twelve-Step Facilitation for Psychiatrists, NIDA Symposium: American Psychiatric Association, New York City, May 2004.

62. The Co-occurring Matrix: Plenary Speaker, Complexities of Co-occurring Conditions Conference, Washington DC, June 2004.

63. Addictions and Suicide in Acute Psychiatric Patients: Conference Committee, Complexities of Co-occurring Conditions Conference, Washington DC, June 2004.

64. New Medications in Addictions Recovery: Washington State Co-occurring Disorders conf, Yakima, Sept 2004

65. Spirituality and Recovery: Am Accad Addictions Psychiatry, national conference, Washington DC, Dec 2004

66. Use of Clinical Data Bases in QI and Research Publications: University of Hawaii Grand Rounds, March 2005

67. Spirituality and 12 Step Meetings: What is the Evidence? American Society of Addiction Medicine, Dallas, April 2005

68. Addictions and Suicide: Texas State Mental Health Conference Plenary, Austen, July 2005

69. The Co-occurring Matrix: Texas State Mental Health Conference, Austen, July 2005

70. Co-occurring Disorders: Inpatient Treatment Program Design: Alaska Psychiatric Institute, September 2005

71. Co-occurring Disorders: State of the Art: Washington State Annual COD Conference, Wenatchee, September 2005

72. Relapse Preventions Medications: Washington State Medical Convention, Tacoma, September 2005

73. Relapse Prevention Medications: Alaska State Addictions Conf, Anchorage Oct 2005


23

74. Models of Treatment of Co-occurring Disorders: British Columbia Addictions Conference, November 2005

75. Addictions and Suicide Workshop: University of British Columbia Addictions Conference, Vancouver BC, November 2005

76. Co-occurring Disorders: Schizophrenia, ASAM National Convention, San Diego, May 2006

77. Co-occurring 101: ASAM State of the Art in Addictions Medicine , Chicago, October 2006

78. The Co-occurring Matrix: National Co-Sig Conference, CSAT, Washington DC, March 2007

79. Substance induced or Not, Symposium: ASAM National Conference, Miami, April 2007.

80. Addictions and Suicide, AAAP US Psychiatric and Mental Health Congress, Orlando, October 2007.

81. Physician Addictions and Recovery Issues: US Psychiatric and Mental Health Congress, Orlando, October 2007.

82. Meds and Metabolics: Medical issues in managing patients with severe mental illness taking antipsychotics and other medications: CHAMMP Regional Conference, Seattle, November 2007.

83. Recovery: Live, from the patients view: Washington Society of Addiction Medicine, Seattle, March 2008.

84. 12-Step Issues in Recovering Physicians: Regional Conference on Physician Health, Seattle, September 2008

85. Addictions and Suicide ( CSAT Sponsored Symposium) American Academy of Addiction Psychiatry national convention, Boca Raton Florida Dec 2009

86. The Role of 12 Step Programs and Spirituality in Physician Recovery, American Academy of Addiction Psychiatry national convention, Boca Raton Florida Dec 2009

87. Addictions and Suicide ( CSAT Sponsored Symposium) American Society of Addiction Medicine, national convention, San Francisco, Apr 2010

88. Benzodiazepine Addiction and Abuse: Key issues, California Society of Addiction Medicine, Los Angeles, California, Sept 2010

89. Medications in Addictions Treatment and Recovery ( with Video interviews) : Washington State Co-occurring Disorders Conference, Oct 2011

90. 12 Step Facilitation for Persons with Co-occurring Disorders: Washington State Co-occurring Disorders Conference, Oct 2011

91. Addictions and Suicide ( CSAT Sponsored Symposium) National Conference on Addiction Disorders, San Diego, Nov 2011


24

92. Medications Assisted Treatment: national webcast, The National Center for State Courts, Willamsburg, VA, Dec 2011

93. Brief Interventions: American Academy of Addiction Psychiatry national convention, Scottsdale Arizona, Dec 2011

94. Sedative Hypnotics: American Academy of Addiction Psychiatry national convention, Scottsdale Arizona, Dec 2011

95. Sedative Hypnotics: Board Prep Course AAAP national convention, Turnberry Island Florida 2012

96. Brief Interventions: Board Prep Course AAAP national convention, Turnberry Island, Florida, 2012

97. Twelve Step Facilitation Workshop AAAP national convention, Turnberry Island, Florida, 2012


25

Current Research Interests:

1. Suicide and Addiction

• Substance related suicide attempts, substance induced mood disorders, and health services implications in psychiatric ER and Inpatients (with Dr. Yuodelis-Flores)

• Borderline PD’s, addiction treatment (with suboxone and DBT) and recovery (Co-PI with Linehan, funded NIDA RO1)

• Ongoing clinical treatment programs in these areas, integrating substance intervention, suicide intervention, in acute psychiatric inpatients, with associated health services research at Harborview Medical Center

2. Twelve Step Facilitation:

• 12 step facilitation for Psychiatrists, developing methods which can be readily understood and used by psychiatrists (with Galanter M, American Academy of Addiction Psychiatry National Meeting presentation in 12/03, 12/06 which may become R23)

• Ongoing model used in University of Washington resident and medical student addictions curriculum, developed since 1985

3. Health Services Research and Treatment Outcomes in Severely Mentally Ill Dually Diagnosed Outpatients./ Severely Ill person with Addictions

• Ongoing evaluations of illness severities, treatment types and intensities in measuring the process and outcomes of treatment in this population

• Special focus on integrated dual diagnosis treatment models, representative payee models, and contingency management models. CSAT TIP, previous NIDA grants

• Ongoing clinical programs at Harborview Community Mental Health Center

• Medical, metabolic, and other problems, and their management, linkage, and outcomes

• Harm reduction approaches to high cost/high morbidity alcoholics using harm reduction approaches integrated with injectable naltrexone

4. Contingency Management Models of Treatment for Methamphetamine and other Substance Abuse in Community Mental Health Center patients, with John Roll PhD

• NIDA grant 1R01DA022476-01A1 from 9/30/2007 through 8/31/2011

• Methamphetamine presentations in Psychiatric Emergency and Inpatient populations (with Dr Pasic)

• Etg based CM for alcohol dependency in SMI patients

5. Medications in Addictions Recovery


26

• Alcohol Relapse Prevention Medications • Opiate addictions treatment with agonists, mixed agents and blockers • Injectable psychiatric medications in SMI/COD persons

Z:\cv\RIES CV 082808.doc mac 2/11/13

Documents

Curriculum Vitae - University of Washingtondepts.washington.edu/psychadd/RIES_CV_1-2013R.pdfduring ECT. Biological Psychiatry 20:94-119, 1985. 23. Ries RK: DSM-III implications of